Funding and Investments

GSK plans to invest in several UK manufacturing sites and to close its Slough site in conjunction with the sale of the Horlicks brand manufactured in Slough.

BIO report measures decade-long investment and acquisition trends for emerging biotech companies.

A loan from the European Investment Bank will give BiondVax resources for Phase III trials and a manufacturing facility for its universal flu vaccine.

GSK invests $139 million to expand production capacity for Benlysta (belimumab) in Rockville, MD.

Univercells received a grant from the Bill & Melinda Gates Foundation for the development of a vaccine manufacturing platform.

Oxford Genetics received £1.61 million from Innovate UK to explore computational and synthetic biology approaches for optimized mammalian bioproduction.

DuPont received a grant from the Bill & Melinda Gates Foundation to produce pharmaceutical proteins.

BMS changes its US geographic footprint with R&D investments and closures.

Despite some progress, pharmaceutical companies have a long way to go in making their products accessible and affordable, this year's study finds.

The company invested more than €250 in production in China.

Oxford Genetics has secured a GBP1 million capital from investment group Mercia Technologies to support its growth strategy in delivering new services for cancer-fighting gene-therapy technologies.

The company invested more than CHF 100 million in a new Delaware manufacturing plant.

The company invested in a new cGMP facility located in Berlin, Germany.

The department gave Moderna $8.2 million to accelerate development of an mRNA-based Zika vaccine.

Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.

Through the Glycoscience Program, the National Institute of Health will contribute $10 million to advance the study of carbohydrates and the compounds that interact with them.

Six grants from the NIH will help identify variants in the genome’s regulatory regions that affect disease risk, using new computational approaches.

GSK announces it will invest $95 million to launch a US-based non-profit research institute, Altius, to research technologies and approaches in understanding gene control.

Syncona and Kite Pharma announced separate investments into T-cell therapies to fight cancerous tumors.

Dalton Pharma Services announced it was awarded funding from ISTPCanada for its project to develop vaccines for respiratory syncytial virus and parainfluenza type 3.

Unum Therapeutics raised $12 million in Series A funding for its development of antibody-coupled T cell receptors (ACTRs) for the treatment of nonspecific tumor cells.

OCE and OBI partner with CQDM on $3 million inter-provincial drug discovery innovation programs.

Gene therapy, immune-oncology, and digital healthcare technologies offer investors promise for innovation investments.

Lilly1s Cyramza is the first FDA-approved treatment for advanced gastric cancer after prior chemotherapy.

Life-sciences companies continue upward momentum in 2014.

Frenzy cools as investors seeking a quick return turn elsewhere.

Caution should be taken when planning to crowdfund a biopharmaceutical startup.

The JOBS Act and FDASIA show early signs of accelerating drug development.

Early-stage companies are now embraced by buyers of new issues.

Pharmaceutical companies have stepped up gene therapy development in the wake of the approval of Glybera in 2012.